COLLABORATION AND CONSENSUS
IN THE SEARCH FOR A CURE

Since 2001, the International Myeloma Working Group's achievements have changed the landscape of myeloma research. This collaborative effort has brought about breakthroughs in treatment options and diagnostic systems that prolong lives. The IMWG consists of nearly 200 leading myeloma researchers from around the world who collaborate on a broad range of myeloma research projects. Their work focuses on protocols to provide a more durable remission for myeloma patients while improving quality of life, and addressing the needs of both myeloma patients and the physicians who treat them.

IMWG Publications

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of 18fluorodeoxyglucose (18F-FDG) PET/CT in patients with multiple myeloma and other plasma cell

  • Second primary malignancies in multiple myeloma: an overview and IMWG consensus

    Therapeutic advancements following the introduction of autologous stem cell transplantation and novel agents have significantly improved clinical outcomes for patients with multiple myeloma (MM).